Page 4 - David Coman News Today

Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE ...

RALEIGH - Science 37, a clinical research organization with dual headquarters in Raleigh and Los Angeles, is set to become a publicly traded company after its

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Photo by Geber86/Getty Images Science 37, a decentralized clinical trial operating system developer, has shared its going public through a merger with special purpose acquisition company LifeSci Acquisition II Corp. Upon completion of the deal, which is expected to close in the third quarter of 2021, the combined company will operate as Science 37 and will trade on the NASDAQ under the ticker symbol “SNCE.” Science 37 will have an initial enterprise value of approximately $1.05 billion. Th...

Science 37, Inc., the Los Angeles, CA-based developer of the Decentralized Clinical Trial Operating System™, and LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors, entered into a definitive business combination agreement. Upon closing of the proposed transaction, the combined company will operate as Science 37 and is expected to be listed on the NASDAQ under the ticker symbol “SNCE�...

Search jobs 07-May-2021 Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical resea...

Science 37® and Xperiome™ Partner to Increase the Efficiency and Speed of Rare Disease Studies for Patients and Providers Using Science 37s decentralized clinical trial model, the partnership offers Xperiomes research-ready, rare disease patients more study opportunities with less burden. News provided by Share this article Share this article LOS ANGELES, March 11, 2021 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, announced today a partnership with Xperi...

Science 37® and Medgate Partner to Further Globalize Decentralized Clinical Trials With a presence in Europe, Asia-Pacific, and the Middle East, Medgate extends the Science 37 Decentralized Clinical Trial Operating System--enabling more provider and patient research participation. News provided by Share this article Share this article LOS ANGELES, March 2, 2021 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, announced today a strategic partnership with Medgate...

Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy.

/PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced a premier partnership program, Science 37 Certified, designed...